Electronic Supplementary Material (ESI) for Journal of Materials Chemistry B. This journal is © The Royal Society of Chemistry 2023

1

Supporting Information

2 Glycolysis Inhibition for Synergistic Phototherapy of Triple-

3 Negative Breast Cancer

4 Yuqian Fu^{a†}, Tingjie Bai^{b†}, Panpan Xue^{b†}, Qi Chen^a, Weili Deng^a, Shuangqian Yan^{b*},

5 Xuemei Zeng^{a*}

6 a Key Laboratory of Microbial Pathogenesis and Interventions of Fujian Province

7 University, Biomedical Research Center of South China, College of Life Sciences, Fujian

8 Normal University, 1 Keji Road, Fuzhou 350117, PR China

9 ^b The Straits Institute of Flexible Electronics (SIFE, Future Technologies), The Straits

10 Laboratory of Flexible Electronics (SLoFE), Fujian Normal University, Fuzhou 350117,

11 Fujian, China

12 † Y. Fu, T. Bai and P. Xue contributed equally.

- 13 * Corresponding authors.
- 14 E-mail: ifeshqyan@fjnu.edu.cn, xmzeng@fjnu.edu.cn
- 15
- 16



Figure S1. (a, b) UV-vis absorption spectra of ICG solution (2.5, 5, 7.5, 10, and 15 μg/mL)

18 (a) and its standard curve (b) calculated by absorption at 808 nm from (a).



21 Figure S2. H1-NMR spectra of supernatant in DMSO-d6.



26 irradiation for different time points (0, 2, 4, 6, 8, and 10 min). The concentration of Lipo

27 and imLipo used is 100 $\mu g/mL.$



29 Figure S4. Colloidal stability of imLipo. The hydrodynamic size and PDI value of imLipo

30 during storage in PBS buffer supplemented with 10% FBS for different days.



- Figure S5. The fluorescent intensity of 4T1 incubated with 50 μg/mL FITC-imLipo at various time points (0, 1, 2, 4, 6, and 12 h).

- 35 36





39 Figure S6. Synergistic factor of imLipo, iLipo+L, and imLipo+L calculated from cell

40 viability results in Figure 2a, b.



42 Figure S7. Cell viability of 4T1 cells incubated with various concentrations of iLipo and 43 imLipo and exposed to laser illumination (808 nm, 0.5 W/cm², 10 min) in an N_2 44 atmosphere.



48 Figure S8. Relative ATP contents of 4T1 cells treated with different concentrations of 49 mannose for 24 h. **P < 0.01, ****P < 0.0001 and ns: not significant (p > 0.05), analyzed 50 by one-way ANOVA, followed by Dunnett's multiple comparisons test. Data represent 51 mean \pm s.d.



55 Figure S9. (a) Immunofluorescence images of 4T1 cells treated with different 56 concentrations of Man for 24 h. Green stained with HSP90, Blue stained with DAPI. Scale 57 bars are 40 μ m. (b) Statistical analysis the fluorescent intensity in (a). **P < 0.01, ****P 58 < 0.0001 and ns: not significant (p > 0.05), analyzed by one-way ANOVA, followed by 59 Dunnett's multiple comparisons test. Data represent mean \pm s.d.



61 Figure S10. Western blotting images of HPS90 protein (a) from 4T1 cells received with

62 various treatments and corresponding statistical results (b) from a.



$HIF\text{-}1\alpha/DAPI$



64

- 65 Figure S11. Immunofluorescence images of 4T1 cells incubated with indicated probe (400
- 66 $\,\mu g/mL)$ and stained with HIF-1a. Scale bars are 40 $\mu m.$



- 69 Figure S12. Fluorescence images of 4T1 cells treated with 400 µg/mL imLipo followed
- 70 by laser irradiation and stained with 2-NBDG.



Figure S13. Extracellular acidification rate (a) and slope (b) of 4T1 cells with different treatments. The concentration of mannose and imLipo is 400 μ g/mL and 400 μ g/mL. **P < 0.01, ****P < 0.0001 and ns: not significant (p > 0.05), analyzed by one-way ANOVA, followed by Dunnett's multiple comparisons test. Data represent mean ± s.d.



79 Figure S14. The fluorescent images of 4T1 treated with indicated treatments and stained

80 with RDPP. Scale bars are 40 μ m.



Figure S15. The fluorescent images of intracellular ${}^{1}O_{2}$ of 4T1 cells under various 84 treatments. The concentration of Lipo, iLipo, mLipo, and imLipo is 400 μ g/mL. Scale

- bars are 30 $\mu m.$



- Annexin-FITC
 88 Figure S16. The apoptosis results of 4T1 cells under various treatments in the N₂
- 89 atmosphere.

95 Figure S18. (a) Schematic illustration of tumor therapy. (b, c) Survival rates (b) and body
96 weights (c) of mice received various treatments. The usage of injected nanoplatform is 2
97 mg per mouse.